PMID- 15090460
OWN - NLM
STAT- MEDLINE
DCOM- 20050209
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 104
IP  - 4
DP  - 2004 Aug 15
TI  - Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by 
      fluorescence in situ hybridization and quantitative analysis of mRNA levels.
PG  - 1120-6
AB  - The t(11;14)(q13;q32) is the most common translocation in multiple myeloma (MM), 
      resulting in up-regulation of cyclin D1. We used a segregation fluorescence in 
      situ hybridization (FISH) assay to detect t(11;14) breakpoints in primary MM 
      cases and real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to 
      quantify cyclin D1 and MYEOV (myeloma overexpressed) expression, another putative 
      oncogene located on chromosome 11q13. High levels of cyclin D1 mRNA (cyclin 
      D1/TBP [TATA box binding protein] ratio > 95) were found exclusively in the 
      presence of a t(11;14) translocation (11/48 cases; P <.00001). In addition, a 
      subgroup of MM cases (15/48) with intermediate to low cyclin D1 mRNA (cyclin 
      D1/TBP ratio between 2.3 and 20) was identified. FISH analysis ruled out a t(11; 
      14) translocation and 11q13 amplification in these cases; however, in 13 of 15 
      patients a chromosome 11 polysomy was demonstrated (P <.0001). These results 
      indicate an effect of gene dosage as an alternative mechanism of cyclin D1 
      deregulation in MM. The absence of chromosome 11 abnormalities in 2 of 15 
      patients with intermediate cyclin D1 expression supports that there are 
      presumably other mechanism(s) of cyclin D1 deregulation in MM patients. Our data 
      indicate that deregulation of MYEOV is not favored in MM and further strengthens 
      the role of cyclin D1 overexpression in lymphoid malignancies with a 
      t(11;14)(q13;q32) translocation.
FAU - Specht, Katja
AU  - Specht K
AD  - Institute of Pathology, GSF-National Research Center for Environment and Health 
      Ingolstadter Landstrasse 1, D-85764 Neuherberg, Germany.
FAU - Haralambieva, Eugenia
AU  - Haralambieva E
FAU - Bink, Karin
AU  - Bink K
FAU - Kremer, Marcus
AU  - Kremer M
FAU - Mandl-Weber, Sonja
AU  - Mandl-Weber S
FAU - Koch, Ina
AU  - Koch I
FAU - Tomer, Raju
AU  - Tomer R
FAU - Hofler, Heinz
AU  - Hofler H
FAU - Schuuring, Ed
AU  - Schuuring E
FAU - Kluin, Philip M
AU  - Kluin PM
FAU - Fend, Falko
AU  - Fend F
FAU - Quintanilla-Martinez, Leticia
AU  - Quintanilla-Martinez L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040413
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (MYEOV protein, human)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA, Messenger)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Chromosomes, Human, Pair 11
MH  - Chromosomes, Human, Pair 14
MH  - Cyclin D1/analysis/*genetics
MH  - Gene Dosage
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Multiple Myeloma/*genetics/pathology
MH  - Oncogene Proteins/analysis/genetics
MH  - Osteolysis/pathology
MH  - Proto-Oncogene Proteins
MH  - RNA, Messenger/*analysis
MH  - Translocation, Genetic
EDAT- 2004/04/20 05:00
MHDA- 2005/02/11 09:00
CRDT- 2004/04/20 05:00
PHST- 2004/04/20 05:00 [pubmed]
PHST- 2005/02/11 09:00 [medline]
PHST- 2004/04/20 05:00 [entrez]
AID - S0006-4971(20)43553-0 [pii]
AID - 10.1182/blood-2003-11-3837 [doi]
PST - ppublish
SO  - Blood. 2004 Aug 15;104(4):1120-6. doi: 10.1182/blood-2003-11-3837. Epub 2004 Apr 
      13.